BioNTech SE (BNTX)
| Market Cap | 21.70B -12.8% |
| Revenue (ttm) | 2.75B -23.2% |
| Net Income | -1.67B |
| EPS | -6.68 |
| Shares Out | 247.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 724,190 |
| Open | 85.60 |
| Previous Close | 85.86 |
| Day's Range | 84.89 - 87.94 |
| 52-Week Range | 79.52 - 124.00 |
| Beta | 1.33 |
| Analysts | Buy |
| Price Target | 114.00 (+30.27%) |
| Earnings Date | Nov 3, 2026 |
About BNTX
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli... [Read more]
Financial Performance
In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for BNTX stock is "Buy." The 12-month stock price target is $114.0, which is an increase of 30.27% from the latest price.
News
BioNTech price target lowered to $106 from $114 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on BioNTech (BNTX) to $106 from $114 and keeps an Overweight rating on the shares.
BioNTech price target lowered to $108 from $114 at BofA
BofA analyst Tazeen Ahmad lowered the firm’s price target on BioNTech (BNTX) to $108 from $114 and keeps a Buy rating on the shares.
BioNTech price target lowered to $125 from $135 at UBS
UBS lowered the firm’s price target on BioNTech (BNTX) to $125 from $135 and keeps a Buy rating on the shares.
BioNTech SE Earnings Call Transcript: Q3 2026
Q3 revenue declined to €1.3B on lower COVID-19 vaccine demand, while FY revenue guidance rose to €1.7B–€1.9B. Oncology progress included encouraging gotistobart and pumitamig combination data, alongside trial and safety uncertainties.
BioNTech SE Earnings release: Q3 2026
BioNTech SE released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
BioNTech SE Slides: Q3 2026
BioNTech SE has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart ...
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
BioNTech, DualityBiologics report DYNASTY-Breast02 met primary endpoint
BioNTech (BNTX) and DualityBiologics announced that the DYNASTY-Breast02 global Phase 3 clinical trial met its primary endpoint demonstrating a statistically significant, yet modest improvement in pro...
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Bre...
BioNTech, Bristol Myers announces data from Phase 2 ROSETTA Lung-107 trial
BioNTech (BNTX) and Bristol Myers Squibb Company (BMY) announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific imm...
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2 ROS...
Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Offers Upside, According to Wall Street?
Moderna ($MRNA) and BioNTech ($BNTX) are biotech stocks focused on cancer vaccines as they enter their next growth phase. According to TipRanks Comparison Stock tool, one stock offers upside potential...
BioNTech, Gilead to test drug combination in advanced breast cancer trial
Germany's BioNTech said on Thursday it had teamed up with Gilead Sciences to test its experimental cancer therapy in combination with the US drugmaker's approved treatment in patients with a form of...
BioNTech announces collaboration, supply agreement with Gilead
BioNTech (BNTX) announced a clinical trial collaboration and supply agreement with Gilead Sciences (GILD) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate sacituzum...
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
MAINZ, Germany, October 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (“Gilead”) to evaluate pumitamig...
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026....
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
MAINZ, Germany, October 19, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its late-stage oncology pipeline with 16 abstracts spanning the Company's...
BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)
BioNTech investors absorbed a 7.13% loss when the AHEAD-MERIT trial of BNT113 missed its progression-free survival primary endpoint. An investigation is underway into whether the Company's statements ...
BioNTech price target lowered to $132 from $136 at Canaccord
Canaccord lowered the firm’s price target on BioNTech (BNTX) to $132 from $136 and keeps a Buy rating on the shares. The firm updated its model following the BNT113 (FixVac)…
BioNTech cancer vaccine trial PFS miss ‘not surprising,’ says Evercore ISI
After BioNTech (BNTX) announced its fixed combination vaccine, BNT113, missed one of its primary endpoints of improved progression free survival when combined with pembrolizumab in metastatic HPV16+ h...
Citi still sees development path for BNT113 despite study miss
Citi keeps a Buy rating on BioNTech (BNTX) with a $125 price target after BNT113 did not demonstrate a statistically significant progression-free survival benefit when added to Merck’s pembrolizumab i...
BMO says BioNTech PFS miss adds to mRNA setbacks, shares likely under pressure
BMO Capital analyst Evan David Seigerman notes BioNTech (BNTX) announced its fixed combination vaccine, BNT113, missed one of its primary endpoints of improved progression free survival when combined ...
BioNTech reports AHEAD-MERIT trial did not meet first dual primary endpoint
06:46 EDT BioNTech (BNTX) reports AHEAD-MERIT trial did not meet first dual primary endpoint
BioNTech’s BNT113 doesn’t meet dual primary endpoint in Phase 2/3 cancer trial
BioNTech (BNTX) announced the first topline results from the AHEAD-MERIT Phase 2/3 clinical trial for its investigational mRNA cancer immunotherapy BNT113, tenu-ra. The clinical trial is evaluating BN...